Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice

Michael Imboden, Michael W Riggs, Deborah A. Schaefer, E. Jane Homan, Robert D. Bremel

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

At present no completely effective treatments are available for Cryptosporidium parvum infections in humans and livestock. Based on previous data showing the neutralizing potential of a panel of monoclonal antibodies developed against C. parvum, and based on the fact that innate immune peptides and enzymes have anticryptosporidial activity, we engineered several of these antibodies into antibody-biocide fusion proteins. We hypothesized that the combination of high-affinity antibody targeting with innate immune molecule-mediated killing would result in a highly effective new antiprotozoal agent. To test this hypothesis, we expressed antibody-biocide fusion proteins in a mammalian cell culture system and used the resulting products for in vitro and in vivo efficacy experiments. Antibody-biocide fusion proteins efficiently bound to, and destroyed, C. parvum sporozoites in vitro through a membrane-disruptive mechanism. When antibody-biocide fusion proteins were administered orally to neonatal mice in a prophylactic model of cryptosporidiosis, the induction of infection was reduced by as much as 81% in the mucosal epithelium of the gut, as determined on the basis of histopathological scoring of infectious stages. Several versions of antibody fusion proteins that differed in antigen specificity and in the biocide used had strong inhibitory effects on the initiation of infection. The results lay the groundwork for the development of a new class of antimicrobials effective against Cryptosporidium.

Original languageEnglish (US)
Pages (from-to)1385-1392
Number of pages8
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Cryptosporidium parvum
Disinfectants
Antibodies
Infection
Proteins
Antiprotozoal Agents
Cryptosporidiosis
Sporozoites
Cryptosporidium
Antibody Affinity
Livestock
Epithelium
Cell Culture Techniques
Monoclonal Antibodies
Antigens
Peptides
Membranes
Enzymes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice. / Imboden, Michael; Riggs, Michael W; Schaefer, Deborah A.; Homan, E. Jane; Bremel, Robert D.

In: Antimicrobial Agents and Chemotherapy, Vol. 54, No. 4, 04.2010, p. 1385-1392.

Research output: Contribution to journalArticle

Imboden, Michael ; Riggs, Michael W ; Schaefer, Deborah A. ; Homan, E. Jane ; Bremel, Robert D. / Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice. In: Antimicrobial Agents and Chemotherapy. 2010 ; Vol. 54, No. 4. pp. 1385-1392.
@article{323f311e34f94be8aac23e8a84652e1d,
title = "Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice",
abstract = "At present no completely effective treatments are available for Cryptosporidium parvum infections in humans and livestock. Based on previous data showing the neutralizing potential of a panel of monoclonal antibodies developed against C. parvum, and based on the fact that innate immune peptides and enzymes have anticryptosporidial activity, we engineered several of these antibodies into antibody-biocide fusion proteins. We hypothesized that the combination of high-affinity antibody targeting with innate immune molecule-mediated killing would result in a highly effective new antiprotozoal agent. To test this hypothesis, we expressed antibody-biocide fusion proteins in a mammalian cell culture system and used the resulting products for in vitro and in vivo efficacy experiments. Antibody-biocide fusion proteins efficiently bound to, and destroyed, C. parvum sporozoites in vitro through a membrane-disruptive mechanism. When antibody-biocide fusion proteins were administered orally to neonatal mice in a prophylactic model of cryptosporidiosis, the induction of infection was reduced by as much as 81{\%} in the mucosal epithelium of the gut, as determined on the basis of histopathological scoring of infectious stages. Several versions of antibody fusion proteins that differed in antigen specificity and in the biocide used had strong inhibitory effects on the initiation of infection. The results lay the groundwork for the development of a new class of antimicrobials effective against Cryptosporidium.",
author = "Michael Imboden and Riggs, {Michael W} and Schaefer, {Deborah A.} and Homan, {E. Jane} and Bremel, {Robert D.}",
year = "2010",
month = "4",
doi = "10.1128/AAC.00754-09",
language = "English (US)",
volume = "54",
pages = "1385--1392",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice

AU - Imboden, Michael

AU - Riggs, Michael W

AU - Schaefer, Deborah A.

AU - Homan, E. Jane

AU - Bremel, Robert D.

PY - 2010/4

Y1 - 2010/4

N2 - At present no completely effective treatments are available for Cryptosporidium parvum infections in humans and livestock. Based on previous data showing the neutralizing potential of a panel of monoclonal antibodies developed against C. parvum, and based on the fact that innate immune peptides and enzymes have anticryptosporidial activity, we engineered several of these antibodies into antibody-biocide fusion proteins. We hypothesized that the combination of high-affinity antibody targeting with innate immune molecule-mediated killing would result in a highly effective new antiprotozoal agent. To test this hypothesis, we expressed antibody-biocide fusion proteins in a mammalian cell culture system and used the resulting products for in vitro and in vivo efficacy experiments. Antibody-biocide fusion proteins efficiently bound to, and destroyed, C. parvum sporozoites in vitro through a membrane-disruptive mechanism. When antibody-biocide fusion proteins were administered orally to neonatal mice in a prophylactic model of cryptosporidiosis, the induction of infection was reduced by as much as 81% in the mucosal epithelium of the gut, as determined on the basis of histopathological scoring of infectious stages. Several versions of antibody fusion proteins that differed in antigen specificity and in the biocide used had strong inhibitory effects on the initiation of infection. The results lay the groundwork for the development of a new class of antimicrobials effective against Cryptosporidium.

AB - At present no completely effective treatments are available for Cryptosporidium parvum infections in humans and livestock. Based on previous data showing the neutralizing potential of a panel of monoclonal antibodies developed against C. parvum, and based on the fact that innate immune peptides and enzymes have anticryptosporidial activity, we engineered several of these antibodies into antibody-biocide fusion proteins. We hypothesized that the combination of high-affinity antibody targeting with innate immune molecule-mediated killing would result in a highly effective new antiprotozoal agent. To test this hypothesis, we expressed antibody-biocide fusion proteins in a mammalian cell culture system and used the resulting products for in vitro and in vivo efficacy experiments. Antibody-biocide fusion proteins efficiently bound to, and destroyed, C. parvum sporozoites in vitro through a membrane-disruptive mechanism. When antibody-biocide fusion proteins were administered orally to neonatal mice in a prophylactic model of cryptosporidiosis, the induction of infection was reduced by as much as 81% in the mucosal epithelium of the gut, as determined on the basis of histopathological scoring of infectious stages. Several versions of antibody fusion proteins that differed in antigen specificity and in the biocide used had strong inhibitory effects on the initiation of infection. The results lay the groundwork for the development of a new class of antimicrobials effective against Cryptosporidium.

UR - http://www.scopus.com/inward/record.url?scp=77950153280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950153280&partnerID=8YFLogxK

U2 - 10.1128/AAC.00754-09

DO - 10.1128/AAC.00754-09

M3 - Article

C2 - 20086143

AN - SCOPUS:77950153280

VL - 54

SP - 1385

EP - 1392

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 4

ER -